Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience
The coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease. The severe impact on the health system and the high economic cost of non-pharmaceutical interventions, such as lockdowns and international...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/589 |
| _version_ | 1797409060524392448 |
|---|---|
| author | Steven Rockman Beverly Taylor John W. McCauley Ian G. Barr Ray Longstaff Ranbir Bahra |
| author_facet | Steven Rockman Beverly Taylor John W. McCauley Ian G. Barr Ray Longstaff Ranbir Bahra |
| author_sort | Steven Rockman |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease. The severe impact on the health system and the high economic cost of non-pharmaceutical interventions, such as lockdowns and international border closures employed to mitigate the spread of COVID-19 prior to the arrival of effective vaccines, have led to calls for development and deployment of novel vaccine technologies as part of a “100-day response ambition” for the next pandemic. Prior to COVID-19, all of the pandemics (excluding HIV) in the past century have been due to influenza viruses, and influenza remains one of the most likely future pandemic threats along with new coronaviruses. New and emerging vaccine platforms are likely to play an important role in combatting the next pandemic. However, the existing well-established, proven platforms for seasonal and pandemic influenza manufacturing will also continue to be utilized to rapidly address the next influenza threat. The field of influenza vaccine manufacturing has a long history of successes, including approval of vaccines within approximately 100 days after WHO declaration of the A(H1N1) 2009 influenza pandemic. Moreover, many advances in vaccine science and manufacturing capabilities have been made in the past decade to optimize a rapid and timely response should a new influenza pandemic threat emerge. |
| first_indexed | 2024-03-09T04:07:53Z |
| format | Article |
| id | doaj.art-91530cc32ed74158b6af0a480c9ab5d2 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T04:07:53Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-91530cc32ed74158b6af0a480c9ab5d22023-12-03T14:03:42ZengMDPI AGVaccines2076-393X2022-04-0110458910.3390/vaccines10040589Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza ExperienceSteven Rockman0Beverly Taylor1John W. McCauley2Ian G. Barr3Ray Longstaff4Ranbir Bahra5Seqirus Ltd., Parkville, VIC 3052, AustraliaSeqirus Ltd., Maidenhead SL6 8AA, UKThe Francis Crick Institute, London NW1 1AT, UKWHO Collaborating Centre for Reference and Research on Influenza, Melbourne, VIC 3000, AustraliaSeqirus Ltd., Maidenhead SL6 8AA, UKSeqirus Ltd., Maidenhead SL6 8AA, UKThe coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease. The severe impact on the health system and the high economic cost of non-pharmaceutical interventions, such as lockdowns and international border closures employed to mitigate the spread of COVID-19 prior to the arrival of effective vaccines, have led to calls for development and deployment of novel vaccine technologies as part of a “100-day response ambition” for the next pandemic. Prior to COVID-19, all of the pandemics (excluding HIV) in the past century have been due to influenza viruses, and influenza remains one of the most likely future pandemic threats along with new coronaviruses. New and emerging vaccine platforms are likely to play an important role in combatting the next pandemic. However, the existing well-established, proven platforms for seasonal and pandemic influenza manufacturing will also continue to be utilized to rapidly address the next influenza threat. The field of influenza vaccine manufacturing has a long history of successes, including approval of vaccines within approximately 100 days after WHO declaration of the A(H1N1) 2009 influenza pandemic. Moreover, many advances in vaccine science and manufacturing capabilities have been made in the past decade to optimize a rapid and timely response should a new influenza pandemic threat emerge.https://www.mdpi.com/2076-393X/10/4/589influenzapandemicvaccinesvaccine manufacturing |
| spellingShingle | Steven Rockman Beverly Taylor John W. McCauley Ian G. Barr Ray Longstaff Ranbir Bahra Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience Vaccines influenza pandemic vaccines vaccine manufacturing |
| title | Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience |
| title_full | Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience |
| title_fullStr | Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience |
| title_full_unstemmed | Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience |
| title_short | Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience |
| title_sort | global pandemic preparedness optimizing our capabilities and the influenza experience |
| topic | influenza pandemic vaccines vaccine manufacturing |
| url | https://www.mdpi.com/2076-393X/10/4/589 |
| work_keys_str_mv | AT stevenrockman globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience AT beverlytaylor globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience AT johnwmccauley globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience AT iangbarr globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience AT raylongstaff globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience AT ranbirbahra globalpandemicpreparednessoptimizingourcapabilitiesandtheinfluenzaexperience |